This category covers biotechnology and pharmaceutical companies developing therapeutics that target mitochondrial dysfunction, autophagy, and lysosomal pathways in Alzheimer's disease. These approaches address the fundamental cellular energy deficits and protein clearance mechanisms that are central to AD pathogenesis.
Mitochondrial dysfunction is one of the earliest and most prominent features of Alzheimer's disease, preceding clinical symptoms by decades. Impairments in mitochondrial complex IV (cytochrome c oxidase), reduced ATP production, and increased oxidative stress contribute to synaptic failure and neuronal death. Autophagy-lysosomal pathway dysfunction leads to accumulation of damaged proteins and organelles, exacerbating [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) pathology.
Key Companies
Mitochondrial Function Companies
Vandria SA
Focus: Mitochondrial quality control and cellular energetics
| Company | Focus | Mechanism | Stage | |---------|-------|-----------|-------| | Neuromito Therapeutics | Mitochondrial function | Small molecule mitochondrial modulators | Discovery | | MitoRestore Pharmaceuticals | Mitochondrial dynamics | Mitochondrial quality control enhancers | Preclinical | | Cytochrome Therapeutics | Cytochrome c function | Cytochrome c oxidase support | Discovery |
Therapeutic Mechanisms
Mitochondrial Targeting Approaches
Mitochondrial Complex Modulation: Supporting activity of electron transport chain complexes, particularly complex IV (cytochrome c oxidase), which is specifically deficient in AD brains.
ATP Production Enhancement: Improving neuronal energy metabolism through glycolytic and oxidative phosphorylation support.
Mitochondrial Dynamics: Modulating fission/fusion balance to improve mitochondrial quality control and distribution within neurons.
Mitophagy Enhancement: Promoting clearance of damaged mitochondria through the PINK1/Parkin pathway and other autophagy mechanisms.
Autophagy-Lysosomal Pathways
Macroautophagy Enhancement: Increasing formation of autophagosomes to clear protein aggregates.
Lysosomal Function: Enhancing lysosomal enzyme activity and acidification to improve protein degradation.
Chaperone-Mediated Autophagy: Targeting specific proteins for lysosomal clearance via LAMP-2A receptor.
TREM2 Activation: Enhancing microglial phagocytosis through TREM2 signaling to clear amyloid plaques and cellular debris.